Latest News

Antipsychotics for Dementia Pose Wide-Ranging Health Risks


 

FROM THE BMJ

‘Serious Harms’

In an accompanying editorial, Raya Elfadel Kheirbek, MD, and Cristina LaFont, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, said the findings “highlight the need for careful justification of antipsychotic use in dementia care, including a comprehensive assessment of the benefits weighed against a broader range of serious harms than previously acknowledged.”

“Using antipsychotics for the management of dementia-related behaviors requires nuanced decision-making after careful assessment, informed by a personalized approach,” they continued. “Dr. Mok and colleagues call for a critical re-evaluation of antipsychotic use in this clinical setting.”

While the findings add to and expand what was already known, “we need to be clear that they don’t show antipsychotics cause all the adverse outcomes reported,” Masud Husain, DPhil, professor of neurology, University of Oxford, England, said in a statement.

While investigators attempted to use matched controls with dementia who had not received antipsychotics, “the people who were prescribed the drugs may simply have been more vulnerable to some of the conditions that occurred more frequently in them, such as pneumonia and cardiovascular disorders,” said Dr. Husain, who was not part of the research.

Although the study was not designed to explore reverse causality, the findings are important for clinicians who prescribe antipsychotics for patients with dementia, Robert Howard, professor of old age psychiatry, at the University of College London, London, England said in a statement.

“Initiation of these drugs in people with dementia should only ever be under specialist supervision, with involvement of patients and family members in informed discussion and review,” said Dr. Howard, who was not involved in the study.

The study was funded by the National Institute for Health and Care Research. Dr. Mok reported no relevant conflicts. Other authors’ disclosures are included in the original article. Dr. Hussain, Dr. Howard, Dr. Kheirbek, and Dr. LeFon reported no relevant conflicts.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

New Data Support Viagra for Alzheimer’s Prevention
MDedge Psychiatry
FDA Issues New Guidance for Early Alzheimer’s Drug Development
MDedge Psychiatry
Human Brains Are Getting Bigger: Good News for Dementia Risk?
MDedge Psychiatry
Smartphone App Detects Early Signs of Frontotemporal Dementia
MDedge Psychiatry
Prevalence of Dementia in Homeless Twice That in Housed
MDedge Psychiatry
Chronic Pain Linked to Accelerated Brain Aging
MDedge Psychiatry
Delirium Linked to a Threefold Increased Risk for Dementia
MDedge Psychiatry
One-Minute Speech Test Could Help Assess Dementia Risk
MDedge Psychiatry
Time Wasted to Avoid Penalties
MDedge Psychiatry
In Lecanemab Alzheimer Extension Study, Placebo Roll-Over Group Does Not Catch Up
MDedge Psychiatry